MA38675A1 - Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués utiles pour inhiber la replication de l'hepatite c (hcv) - Google Patents

Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués utiles pour inhiber la replication de l'hepatite c (hcv)

Info

Publication number
MA38675A1
MA38675A1 MA38675A MA38675A MA38675A1 MA 38675 A1 MA38675 A1 MA 38675A1 MA 38675 A MA38675 A MA 38675A MA 38675 A MA38675 A MA 38675A MA 38675 A1 MA38675 A1 MA 38675A1
Authority
MA
Morocco
Prior art keywords
derivatives
fluoro
substituted
hcv
hepatitis
Prior art date
Application number
MA38675A
Other languages
English (en)
Inventor
Mark Smith
Klaus G Klumpp
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of MA38675A1 publication Critical patent/MA38675A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analyzing Materials Using Thermal Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des dérivés de nucléosides 4'-fluoro-2'-méthyle substitués, des compositions pharmaceutiques comprenant lesdits dérivés et des méthodes d'utilisation de ces composés et/ou des compositions de ceux-ci, pour le traitement du vhc.
MA38675A 2013-05-16 2014-05-15 Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués utiles pour inhiber la replication de l'hepatite c (hcv) MA38675A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824030P 2013-05-16 2013-05-16
PCT/US2014/038287 WO2014186637A1 (fr) 2013-05-16 2014-05-15 Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués

Publications (1)

Publication Number Publication Date
MA38675A1 true MA38675A1 (fr) 2017-12-29

Family

ID=51895938

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38675A MA38675A1 (fr) 2013-05-16 2014-05-15 Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués utiles pour inhiber la replication de l'hepatite c (hcv)
MA46490A MA46490A1 (fr) 2013-05-16 2014-05-15 Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA46490A MA46490A1 (fr) 2013-05-16 2014-05-15 Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués

Country Status (23)

Country Link
US (1) US9895442B2 (fr)
EP (1) EP2996695B1 (fr)
JP (1) JP6366693B2 (fr)
KR (1) KR102241198B1 (fr)
CN (1) CN105307662B (fr)
AU (1) AU2014265293B2 (fr)
BR (1) BR112015028764B1 (fr)
CA (1) CA2912682C (fr)
CL (1) CL2015003357A1 (fr)
CR (1) CR20150648A (fr)
EA (1) EA035301B1 (fr)
HK (2) HK1217294A1 (fr)
IL (1) IL242605B (fr)
MA (2) MA38675A1 (fr)
MX (1) MX2015015782A (fr)
MY (1) MY186547A (fr)
NZ (1) NZ714927A (fr)
PE (1) PE20160120A1 (fr)
PH (1) PH12015502588A1 (fr)
SG (1) SG11201509424VA (fr)
UA (1) UA123533C2 (fr)
WO (1) WO2014186637A1 (fr)
ZA (1) ZA201509056B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861611B1 (fr) 2012-05-25 2016-07-13 Janssen Sciences Ireland UC Nucléosides dýuracyle spirooxetane
RS61767B1 (sr) 2012-12-21 2021-05-31 Janssen Biopharma Inc 4'-fluor-nukleozidi, 4'-fluor-nukleotidi i njihovi analozi za lečenje hcv
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
SG10201804835VA (en) * 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CN106661076A (zh) * 2014-06-24 2017-05-10 艾丽奥斯生物制药有限公司 制备取代的核苷酸类似物的方法
MA41441A (fr) * 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
EP3355991A1 (fr) * 2015-09-29 2018-08-08 Janssen Pharmaceuticals, Inc. Polythérapie pour le traitement d'une du vhc
WO2018017989A1 (fr) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Schémas de polythérapie pour le traitement de génotypes du vhc
CN108424431B (zh) * 2017-09-06 2021-04-20 上海兆维科技发展有限公司 α-尿嘧啶核苷的制备方法
EP3684374A4 (fr) * 2017-09-21 2021-06-16 Riboscience LLC Dérivés nucléosidiques à substitution 4'-fluoro-2'-méthyle utilisés comme inhibiteurs de la réplication de l'arn du vhc
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
WO2019173602A1 (fr) * 2018-03-07 2019-09-12 Emory University Compositions thérapeutiques à base de nucléosides et de nucléotides contenant 4-halogène et utilisations associées
CN112142809B (zh) * 2020-09-29 2022-03-22 佛山科学技术学院 尿苷酸双丙酸酯基氨基磷酸酯化合物、其药物组合物及其制备方法和应用
WO2024086592A2 (fr) * 2022-10-17 2024-04-25 Emory Unversity Compositions thérapeutiques à base de nucléosides et de nucléotides contenant du 4'-halogène et utilisations associées

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU498131B2 (en) 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
US4147864A (en) 1975-02-20 1979-04-03 Ciba-Geigy Corporation Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds
US4322347A (en) 1978-04-03 1982-03-30 Bristol-Myers Company 2-Carbamoyloxymethyl-penicillin derivatives
WO1986006380A1 (fr) 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Composes antibacteriens, utilisation et preparation
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
AU723730B2 (en) 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998040381A1 (fr) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibiteurs de l'enzyme impdh
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
ATE283865T1 (de) 1997-08-11 2004-12-15 Boehringer Ingelheim Ca Ltd Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
JP2003525200A (ja) 1998-07-27 2003-08-26 イスティトゥト ディ リチェルケ ディ ビオロジア モレコラーレ ピー．アンジェレッティ ソチエタ ペル アツィオニ ポリメラーゼ阻害剤としてのジケト酸誘導体
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1128832A4 (fr) 1998-08-21 2003-03-05 Viropharma Inc Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees
MXPA01002253A (es) 1998-09-04 2003-06-04 Viropharma Inc Metodo para tratar o prevenir infecciones virales y enfermedades asociadas.
BR9913935A (pt) 1998-09-25 2001-06-19 Viropharma Inc Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
ES2405316T3 (es) 1999-03-19 2013-05-30 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima IMPDH
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
WO2001085172A1 (fr) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Nouveaux anti-infectieux
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
JP2005500287A (ja) 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法
PT1401825E (pt) 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (fr) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
EP2335700A1 (fr) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
US7259163B2 (en) 2001-11-02 2007-08-21 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
EP1440068A1 (fr) 2001-11-02 2004-07-28 Glaxo Group Limited Derives d'acyl-dihydro-pyrrole utilises comme inhibiteurs du vhc
CA2488534A1 (fr) 2002-06-21 2003-12-31 Merck & Co., Inc. Derives nucleosidiques utilises comme inhibiteurs de l'arn polymerase virale arn-dependante
US20050020884A1 (en) 2003-02-25 2005-01-27 Hart Charles C. Surgical access system
EP1617848A2 (fr) 2003-04-25 2006-01-25 Gilead Sciences, Inc. Conjugues phosphonate anti-cancereux
DK1625154T3 (da) 2003-05-09 2014-02-24 Boehringer Ingelheim Int Hepatitis c virus ns5b-polymeraseinhibitor-bindende lomme
EP1656093A2 (fr) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides pour traitement des infections a coronavirus, a togavirus et a picornavirus
PT1633766T (pt) * 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
WO2005007810A2 (fr) 2003-06-16 2005-01-27 Grinstaff Mark W Macromolecules et molecules synthetiques fonctionnelles pour l'administration de genes
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
NZ548740A (en) 2004-01-30 2010-06-25 Medivir Ab HCV NS-3 Serine protease inhibitors
MX2007006961A (es) 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.
CA2618335C (fr) 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Phosphoramidates antiviraux
JP2009526850A (ja) 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2442001A (en) 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
WO2008085508A2 (fr) 2007-01-05 2008-07-17 Merck & Co., Inc. Phosphoramidates d'aryle nucléosidiques destinés au traitement de l'infection virale d'arn arn dépendante
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201031675A (en) * 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
WO2011133871A2 (fr) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Dérivés d'extrémité 5'
KR20200052384A (ko) 2010-07-19 2020-05-14 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
CN103209987B (zh) * 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
WO2013019874A1 (fr) 2011-08-01 2013-02-07 Mbc Pharma, Inc. Dérivés à base de vitamine b6 de nucléotides, d'acyclonucléotides et de phosphonates d'acyclonucléosides
JP5982007B2 (ja) * 2011-12-20 2016-08-31 リボサイエンス・エルエルシー Ｈｃｖｒｎａ複製の阻害薬としての２’，４’−ジフルオロ−２’−メチル置換されたヌクレオシド誘導体
WO2013177195A1 (fr) * 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
EP2935304A1 (fr) * 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
RS61767B1 (sr) 2012-12-21 2021-05-31 Janssen Biopharma Inc 4'-fluor-nukleozidi, 4'-fluor-nukleotidi i njihovi analozi za lečenje hcv

Also Published As

Publication number Publication date
KR102241198B1 (ko) 2021-04-15
AU2014265293A1 (en) 2015-12-24
HK1219900A1 (zh) 2017-04-21
CA2912682A1 (fr) 2014-11-20
CA2912682C (fr) 2021-07-06
PE20160120A1 (es) 2016-02-24
SG11201509424VA (en) 2015-12-30
CN105307662B (zh) 2019-06-04
NZ714927A (en) 2020-09-25
CL2015003357A1 (es) 2016-11-04
JP6366693B2 (ja) 2018-08-01
EA201592184A1 (ru) 2016-04-29
EP2996695B1 (fr) 2022-04-13
EP2996695A4 (fr) 2016-12-14
BR112015028764A2 (pt) 2017-07-25
ZA201509056B (en) 2016-11-30
EA035301B1 (ru) 2020-05-26
CR20150648A (es) 2016-03-09
US20140341847A1 (en) 2014-11-20
JP2016518453A (ja) 2016-06-23
PH12015502588B1 (en) 2016-02-29
UA123533C2 (uk) 2021-04-21
CN105307662A (zh) 2016-02-03
IL242605B (en) 2018-08-30
AU2014265293B2 (en) 2019-07-18
MY186547A (en) 2021-07-26
BR112015028764B1 (pt) 2022-09-27
MX2015015782A (es) 2016-06-02
MA46490A1 (fr) 2021-04-30
US9895442B2 (en) 2018-02-20
HK1217294A1 (zh) 2017-01-06
PH12015502588A1 (en) 2016-02-29
WO2014186637A1 (fr) 2014-11-20
EP2996695A1 (fr) 2016-03-23
KR20160040141A (ko) 2016-04-12

Similar Documents

Publication Publication Date Title
MA38675A1 (fr) Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués utiles pour inhiber la replication de l'hepatite c (hcv)
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MX2021005087A (es) Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae.
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
EA201691931A1 (ru) 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы
EA201590890A1 (ru) Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу
BR112016004919A2 (pt) Inibidores de polimerase de hcv
EA201691554A1 (ru) 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
CL2010001634A1 (es) Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
EA200901080A1 (ru) Новые нуклеозидные аналоги для лечения вирусных инфекций
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201892264A1 (ru) Производные тетрагидроизохинолина
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales